Palisade Bio Announces Canadian Intellectual Property Office Issues Notice Of Allowance For Patent Covering PALI-2108, An Orally Administered PDE4 Inhibitor Prodrug For Ulcerative Colitis
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering PALI-2108, an orally administered PDE4 inhibitor prodrug for ulcerative colitis. The company plans to start Phase 1 human clinical trials by the end of the year.
June 11, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Palisade Bio has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering PALI-2108, an orally administered PDE4 inhibitor prodrug for ulcerative colitis. The company plans to start Phase 1 human clinical trials by the end of the year.
The patent allowance is a significant milestone for Palisade Bio, potentially increasing investor confidence. The upcoming Phase 1 trials could further boost the stock if successful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100